IBD Science for Patients

Combining Forces: How Dual Biologic Therapy Offers New Hope for Children with Refractory IBD

When a child or teenager is diagnosed with paediatric inflammatory bowel disease, getting their gut inflammation under control quickly is essential for their growth, energy, and school life. Advanced treatments called biologic therapies (specialised medications made from living cells) have transformed paediatric care. However, for many young people, standard single-drug treatments do not always bring complete relief. Around 60 per cent of children who start a biologic either do not respond fully or find that the medication loses its effectiveness over time.

When a young patient’s disease remains refractory, meaning it refuses to settle down despite standard biologic drugs, families and medical teams face a difficult question: what comes next?

Now, a new study brings encouraging news. Researchers have evaluated a strategy called dual biologic therapy, where doctors combine two different biologic medications at the same time to help children with severe IBD reach deep, lasting healing.

Demystifying the Science: How Dual Biologic Therapy Works

To understand why combining two biologics can succeed where single drugs fail, it helps to look at how these treatments target inflammation inside the body:

  • Anti-Tumour Necrosis Factor Alpha (Anti-TNF-α): This is a widely used class of biologic medication (such as infliximab or adalimumab). It acts like a widespread shield, blocking a powerful inflammatory chemical called TNF-alpha throughout your entire body to stop immune cells from attacking healthy tissue.
  • Vedolizumab: Unlike broad anti-TNF treatments, vedolizumab is a gut-selective biologic. It acts like a precise, local security guard in your digestive tract, blocking inflammatory white blood cells from entering your gut lining without affecting the rest of your body’s immune system.
  • Dual Biologic Therapy: By combining an anti-TNF medication with vedolizumab, doctors can attack gut inflammation from two completely different angles at the same time.

Inside the Study: Small Scale and Twelve-Month Timeline

Because combining two powerful immune-targeting drugs in young people requires extra caution, researchers conducted a small retrospective cohort study to carefully evaluate safety and effectiveness.

The study analysed 22 treatment episodes in 21 children (17 with Crohn’s disease and 5 with ulcerative colitis) who were treated with combined anti-TNF and vedolizumab therapy between 2020 and 2023. All participants had severe disease that had failed to settle on single biologic drugs. The young patients were treated and monitored over a 12-month follow-up period, with 13 children completing the full year of dual therapy.

Key Findings: High Remission Rates and Deep Tissue Healing

The study revealed that combining anti-TNF therapy with vedolizumab brought significant improvement across several key medical measures:

  1. Rapid Clinical Remission: At the start of the study, only 9 per cent of the children were in clinical remission. After just 3 months on dual biologic therapy, 68 per cent achieved steroid-free clinical remission (meaning their symptoms disappeared without needing corticosteroid drugs). Remission was maintained in 55 per cent of patients at 6 months and 50 per cent at 12 months. Overall, 72 per cent of the children achieved remission at some point during their treatment.
  2. Endoscopic and Histological Healing: Getting rid of daily symptoms is important, but true recovery requires healing the physical lining of the gut. Endoscopic remission (a completely healthy appearance of the bowel wall during a camera check) increased from 5 per cent at baseline to 38 per cent. Furthermore, histological remission (microscopic proof under a laboratory microscope that inflammation has disappeared) rose from 5 per cent to 29 per cent.
  3. Dropping Stool Biomarkers: Levels of faecal calprotectin (a protein measured in a simple stool sample that flags active gut inflammation) dropped dramatically from a heavy average of 930 μg/g down to 500 μg/g at 3 months, 680 μg/g at 6 months, and 255 μg/g at 12 months.
  4. Who Responded Best? Children with ulcerative colitis, those with inflammation located in their colon, and those who had experienced an incomplete response (rather than a total loss of response) to their previous anti-TNF drug showed the strongest trends toward long-term remission.
  5. Safety Monitoring: Because dual therapy increases immune suppression, researchers tracked adverse events closely. Two significant infections occurred during the study (a fungal lung infection and a herpes simplex virus infection), highlighting why children on dual therapy must be monitored carefully by specialist paediatric gastroenterology teams.

Why This Matters to You as a Patient (and Parent)

If you are a young person living with IBD, or a parent supporting a child whose medication has stopped working, this research offers vital encouragement for your healthcare journey:

  1. Proof That You Have Choices Beyond Single Drugs: This study gives you proof that running out of single-drug options does not mean you have run out of options altogether. Combining two targeted biologics can successfully reset your gut lining even when previous treatments have struggled.
  2. Aiming for True, Deep Healing: Seeing that dual therapy improves not just symptoms, but endoscopic and microscopic tissue healing (histological remission), means your body gets a real chance to recover, absorb nutrients properly, and support normal growth.
  3. A Guided Strategy for Difficult Cases: Knowing that patients with colonic involvement and partial anti-TNF responses did best allows you and your paediatric care team to discuss whether personalised precision options are right for your family.

By exploring innovative, multi-targeted approaches, paediatric gastroenterologists are opening new pathways to help children with severe IBD regain their health, freedom, and childhood.

Explore the Research

Leave a comment